GlassScriptPhysician profile
Taymour E Malak
NPI 1104931260
$28,699.88
in general payments reported to CMS, 2019-2025
76 companies · $4,244 in 2025
The $4,244 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,678 · 2020: $3,755 · 2021: $3,982 · 2022: $4,042 · 2023: $4,563 · 2024: $4,436 · 2025: $4,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,115.23 |
| Education | $128.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,037.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,921.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,234.27 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,905.13 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $1,364.03 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $1,314.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,224.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,152.43 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $1,014.26 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $875.92 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $813.18 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $741.15 | 2023-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $673.21 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ardelyx, INC. | $620.25 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $604.13 | 2019-2024 | Xifaxan |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taymour Malak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.